CRISPR

CRISPR1-pheta1

ID
ZDB-CRISPR-210105-8
Name
CRISPR1-pheta1
Previous Names
  • CRISPR1-si:ch211-193c2.2
Target
Sequence
5' - GGAGCTGAACGAGAGGAGTG - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
The first two "G"s were added.
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
vt2 pheta1
Expression
Gene expression in Wild Types + CRISPR1-pheta1
No data available
Phenotype
Phenotype resulting from CRISPR1-pheta1
No data available
Phenotype of all Fish created by or utilizing CRISPR1-pheta1
Phenotype Fish Conditions Figures
Meckel's cartilage decreased area, abnormal pheta1vt2/vt2 standard conditions Fig. 4. with image from Ates et al., 2020
pinocytosis decreased efficacy, abnormal pheta1vt2/vt2 standard conditions Fig. 3. with image from Ates et al., 2020
ventral mandibular arch decreased width, abnormal pheta1vt2/vt2 standard conditions Fig. 7. with image from Ates et al., 2020
pronephros cilium decreased amount, abnormal pheta1vt2/vt2 standard conditions Fig. 3. with image from Ates et al., 2020
ventral mandibular arch decreased width and length, abnormal pheta1vt2/vt2 standard conditions Fig. 4. with image from Ates et al., 2020
pronephros cilium decreased length, abnormal pheta1vt2/vt2 standard conditions Fig. 3. with image from Ates et al., 2020
chondrocyte axis elongation disrupted, abnormal pheta1vt2/vt2 standard conditions Fig. 5. with image from Ates et al., 2020
ventral mandibular arch decreased length, abnormal pheta1vt2/+; vt5Tg standard conditions Fig. 7. with image from Ates et al., 2020
ventral mandibular arch decreased width, abnormal pheta1vt2/vt2; vt4Tg standard conditions Fig. 7. with image from Ates et al., 2020
ventral mandibular arch decreased width, abnormal pheta1vt2/vt2; vt5Tg standard conditions Fig. 7. with image from Ates et al., 2020
chondrocyte axis elongation disrupted, abnormal pheta1vt2/vt2; pheta2vt3/vt3 standard conditions Fig. 5. with image from Ates et al., 2020
cranium decreased length, ameliorated pheta1vt2/vt2; pheta2vt3/vt3 chemical treatment: EC 3.4.22.38 (cathepsin K) inhibitor Fig. 6. with image from Ates et al., 2020
ceratohyal cartilage decreased length, ameliorated pheta1vt2/vt2; pheta2vt3/vt3 chemical treatment: EC 3.4.22.38 (cathepsin K) inhibitor Fig. 6. with image from Ates et al., 2020
ceratohyal cartilage ab1-col2a labeling increased amount, abnormal pheta1vt2/vt2; pheta2vt3/vt3 standard conditions Fig. 5. with image from Ates et al., 2020
ventral mandibular arch decreased width and length, abnormal pheta1vt2/vt2; pheta2vt3/vt3 standard conditions Fig. 4. with image from Ates et al., 2020
Meckel's cartilage decreased area, abnormal pheta1vt2/vt2; pheta2vt3/vt3 standard conditions Fig. 4. with imageFig. 6. with image from Ates et al., 2020
cranium decreased length, abnormal pheta1vt2/vt2; pheta2vt3/vt3 standard conditions Fig. 4. with imageFig. 6. with image from Ates et al., 2020
ventral mandibular arch increased length, abnormal pheta1vt2/vt2; pheta2vt3/vt3 chemical treatment: EC 3.4.22.38 (cathepsin K) inhibitor Fig. 6. with image from Ates et al., 2020
pronephros cilium decreased length, abnormal pheta1vt2/vt2; pheta2vt3/vt3 standard conditions Fig. 3. with image from Ates et al., 2020
ventral mandibular arch decreased width, abnormal pheta1vt2/vt2; pheta2vt3/vt3 control Fig. 6. with image from Ates et al., 2020
Meckel's cartilage ab1-col2a labeling increased amount, abnormal pheta1vt2/vt2; pheta2vt3/vt3 standard conditions Fig. 5. with image from Ates et al., 2020
Meckel's cartilage decreased area, ameliorated pheta1vt2/vt2; pheta2vt3/vt3 chemical treatment: EC 3.4.22.38 (cathepsin K) inhibitor Fig. 6. with image from Ates et al., 2020
pronephros cilium decreased amount, abnormal pheta1vt2/vt2; pheta2vt3/vt3 standard conditions Fig. 3. with image from Ates et al., 2020
ceratohyal bone ossification decreased process quality, abnormal pheta1vt2/vt2; pheta2vt3/vt3 standard conditions Fig. 4. with image from Ates et al., 2020
ceratohyal cartilage decreased width, ameliorated pheta1vt2/vt2; pheta2vt3/vt3 chemical treatment: EC 3.4.22.38 (cathepsin K) inhibitor Fig. 6. with image from Ates et al., 2020
ceratohyal cartilage decreased width, abnormal pheta1vt2/vt2; pheta2vt3/vt3 control Fig. 6. with image from Ates et al., 2020
ceratohyal cartilage decreased length, abnormal pheta1vt2/vt2; pheta2vt3/vt3 standard conditions Fig. 4. with imageFig. 6. with image from Ates et al., 2020
ventral mandibular arch decreased width, abnormal pheta1vt2/vt2; pheta2vt3/vt3 chemical treatment: EC 3.4.22.38 (cathepsin K) inhibitor Fig. 6. with image from Ates et al., 2020
Citations